H.C. Wainwright initiated coverage of Autolus Therapeutics (NASDAQ:AUTL) with a “buy” rating and $45 price target. The stock closed at $30.64 on Oct. 23. Autolus is a UK-based, oncology-focused, autologous cell therapy...
Closely-held Mati Therapeutics’ international patent portfolio has grown to 114 issued patents, including a recently granted U.S. patent, which covers a drug delivery system for administering an ophthalmic drug through...
BTIG launched coverage of Gritstone Oncology (NASDAQ:GRTS) with a “buy” rating and $26 price target. The stock closed at $15.17 on Oct. 22. Gritstone is a clinical-phase oncology company that specializes in focusing a...
IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT)completed an offering of 17,144,314 units at a price of 70 (U.S.) cents each for gross proceeds of approximately $12-million. Each unit consists of one common share of...
Closely-held Scientus Pharma received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art commercial production facility in Whitby, Ontario. “At Scientus Pharma, our main...
Piper Jaffray initiated coverage of Ra Medical Systems (NASDAQ:RMED) with an “overweight” rating and price target of $23. The stock closed at $13.25 on Oct. 19. Ra makes and sells excimer laser products. While it has a...
Shares of Titan Pharmaceuticals (NASDAQ:TTNP) jumped 33% to close at 32 cents on Oct. 18 after A.G.P./Alliance Global Partners initiated coverage of Titan with a “buy” rating and price target of 45 cents. Turnover was a...
In the latest edition of Scientific American online, Dr. Gina Siddiqui, an emergency room doctor at Yale New Haven Hospital, discusses why physicians have incorrectly feared that new technology would make their jobs...
Closely-held Breath Therapeutics appointed Peter Shadday as chief commercial officer to lead the company’s market access activities and product commercialization.
BTIG launched coverage of Y-mAbs Therapeutics (NASDAQ:YMAB) with a “buy” rating and $35 price target. The stock closed at $21.60 on Oct. 15. Y-mAbs is in pivotal trials for the treatment of both primary neuroblastomas...